Capital World Investors
RGLS

Capital World Investors’s Regulus Therapeutics RGLS Stock Holding History

Capital World Investors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-29,458
Closed -$24.5M – 513
2016
Q1 		$24.5M Buy
29,458
+12,666
+75% +$10.1M 0.01% 385
2015
Q4 		$17.6M Hold
16,792
– – ﹤0.01% 434
2015
Q3 		$13.2M Hold
16,792
– – ﹤0.01% 458
2015
Q2 		$22.1M Sell
16,792
-3,994
-19% -$6.44M 0.01% 432
2015
Q1 		$42.3M Buy
20,786
+1,772
+9% +$3.85M 0.01% 382
2014
Q4 		$36.6M Buy
+19,014
New +$33.8M 0.01% 394

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors's RGLS Position: Q2 2016 in Review

Capital World Investors sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 29,458 shares — an estimated $24.5M sold.

Capital World Investors first reported a position in RGLS in Q4 2014 and held it in 6 quarters. The position peaked at $42.3M in Q1 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Capital World Investors reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Capital World Investors sold 29,458 Regulus Therapeutics shares in Q2 2016, an estimated $24.5M.
  • Capital World Investors first reported a position in Regulus Therapeutics in Q4 2014 and held it in 6 quarters.
  • Capital World Investors's Regulus Therapeutics position peaked at $42.3M in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Capital World Investors's 13F filing for Q2 2016, filed 15 Aug 2016.